The FDA highlights increased toxicity risks in patients with DPD deficiency when using Xeloda and 5-FU, urging genetic testing before treatment. DPD deficiency leads to severe side effects from ...
Omitting the 5-fluorouracil (5-FU) bolus from multidrug regimens in patients with advanced gastrointestinal cancers reduces toxicities, such as cytopenia, and does not affect overall survival. Initial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback